

CUMULATIVE INDEX

Volume 32, Numbers 1-4, 1989

- Abortion
 - induced
 - incidence in various countries, 311-312
 - progesterone antagonists in, 403-412
 - Ru 486 in, 308, 405-408
 - recurrent, 520-530
 - anatomic abnormalities in, 529
 - anticardiolipin antibody in, 524-525
 - antipaternal leukocytotoxic activity in, 526-527
 - in autoimmune diseases, 520-525
 - blocking antibodies in, 527
 - genetic causes of, 529
 - immune responses in, 525-526
 - immunotherapy in, 527-529
 - lupus anticoagulant in, 521-524
- Abstinence, periodic, in family planning, 387-399
 - and birth defects, 397
 - calendar rhythm method in, 388-389
 - cervical mucus method in, 389-390, 391
 - efficacy of, 394-396
 - factor affecting use of, 397
 - in lactation, 396
 - and preselection of sex of offspring, 396-397
 - psychosocial impact of, 397-398
 - symptothermal method in, 390-392
 - teaching methods for, 398-399
 - variations in methods of, 392-394
- Acetazolamide in pregnancy, 17
- Acetowhite epithelium in genital papillomavirus infection, 171
- ACTH levels, RU 486 affecting, 405
- Acupuncture for labor induction, in postdate pregnancy, 271
- Acyclovir in herpes simplex infection, in AIDS, 470
- Adhesiolysis, pelvic, lasers in, 580
- β -Adrenergic blockers in pregnancy, 15-16
 - in atrial fibrillation, 35
- Afterload, cardiac, 5
- Age
 - and postdate pregnancy incidence, 230
 - and surgery in breast cancer, 812
- AIDS
 - azidothymidine in
 - in pregnancy, 472
 - as prophylaxis, 495
 - and biology of immunodeficiency virus, 423-425
 - in childhood
 - clinical features of, 478-479
 - definition of, 478
 - epidemiology of, 477-478
 - immune response in, 479
 - neonatal diagnosis of, 480-481
 - perinatal transmission of, 456-458, 481
 - peripartum transmission of, 459-460
 - transmission by breast milk, 458-459, 474
 - treatment of, 481-482
 - and controversies in counseling, 501-504
 - course of, 440-441
 - diagnosis of, 438-440
 - neonatal, 480-481
 - epidemiology of
 - in children, 477-478
 - survey of parturients in hospital settings, 432-435
 - in women, 429-439
 - ethical issues in prevention of, 497-504
 - and guidelines for donor insemination, 593-594
 - immune response in
 - in childhood, 479
 - in pregnancy, 460-462
 - immunology of, 425-428
 - management in pregnancy, 467-475
 - antepartum, 467-472
 - in candidiasis, 471
 - in herpes simplex infection, 470
 - intrapartum, 472-474, 489-490
 - in Kaposi's sarcoma, 472
 - postpartum, 474
 - in *Pneumocystis carinii* pneumonia, 468-470
 - in syphilis, 472
 - in toxoplasmosis, 470-471
 - in tuberculosis, 471-472
 - in military recruits, 435
 - opportunistic infections in, 468-472
 - in pregnancy
 - immune response in, 460-462
 - management of, 467-475
 - and outcome of pregnancy, 462-463
 - transmission to infants, 456-460, 481
 - prenatal counseling in, 445-451
 - checklist for, 453-455
 - prognosis of, 441-443
 - review questions, 517
 - risks for health care workers, 485-495
 - frequency of, 492
 - and management of exposures, 493-495
 - and modes of transmission, 485-488
 - and preventive measures, 488-491
 - tests for HIV antibody in, 425-428, 439-440, 446, 507-508
 - and controversies in screening, 498-501
 - in infants, 480
 - and posttest counseling, 448-451
 - prenatal, disadvantages of, 506-514
 - preoperative, 491
 - and pretest counseling, 447-448
 - transmission of
 - by blood exposure of nonintact skin, 486-487
 - by breast milk, 458-459, 474
 - to health care workers, 485-488
 - by needlestick injuries, 487-488
 - perinatal, 456-458, 481
 - by transfusions, 460
 - universal precautions in, 489
 - in labor and delivery, 489-490
 - in office settings, 489
 - in operating room, 490-491

CUMULATIVE INDEX

Volume 32, Numbers 1-4, 1989

- Abortion
 - induced
 - incidence in various countries, 311-312
 - progesterone antagonists in, 403-412
 - Ru 486 in, 308, 405-408
 - recurrent, 520-530
 - anatomic abnormalities in, 529
 - anticardiolipin antibody in, 524-525
 - antipaternal leukocytotoxic activity in, 526-527
 - in autoimmune diseases, 520-525
 - blocking antibodies in, 527
 - genetic causes of, 529
 - immune responses in, 525-526
 - immunotherapy in, 527-529
 - lupus anticoagulant in, 521-524
- Abstinence, periodic, in family planning, 387-399
 - and birth defects, 397
 - calendar rhythm method in, 388-389
 - cervical mucus method in, 389-390, 391
 - efficacy of, 394-396
 - factor affecting use of, 397
 - in lactation, 396
 - and preselection of sex of offspring, 396-397
 - psychosocial impact of, 397-398
 - symptothermal method in, 390-392
 - teaching methods for, 398-399
 - variations in methods of, 392-394
- Acetazolamide in pregnancy, 17
- Acetowhite epithelium in genital papillomavirus infection, 171
- ACTH levels, RU 486 affecting, 405
- Acupuncture for labor induction, in postdate pregnancy, 271
- Acyclovir in herpes simplex infection, in AIDS, 470
- Adhesiolysis, pelvic, lasers in, 580
- β -Adrenergic blockers in pregnancy, 15-16
 - in atrial fibrillation, 35
- Afterload, cardiac, 5
- Age
 - and postdate pregnancy incidence, 230
 - and surgery in breast cancer, 812
- AIDS
 - azidothymidine in
 - in pregnancy, 472
 - as prophylaxis, 495
 - and biology of immunodeficiency virus, 423-425
 - in childhood
 - clinical features of, 478-479
 - definition of, 478
 - epidemiology of, 477-478
 - immune response in, 479
 - neonatal diagnosis of, 480-481
 - perinatal transmission of, 456-458, 481
 - peripartum transmission of, 459-460
 - transmission by breast milk, 458-459, 474
 - treatment of, 481-482
 - and controversies in counseling, 501-504
 - course of, 440-441
 - diagnosis of, 438-440
 - neonatal, 480-481
 - epidemiology of
 - in children, 477-478
 - survey of parturients in hospital settings, 432-435
 - in women, 429-439
 - ethical issues in prevention of, 497-504
 - and guidelines for donor insemination, 593-594
 - immune response in
 - in childhood, 479
 - in pregnancy, 460-462
 - immunology of, 425-428
 - management in pregnancy, 467-475
 - antepartum, 467-472
 - in candidiasis, 471
 - in herpes simplex infection, 470
 - intrapartum, 472-474, 489-490
 - in Kaposi's sarcoma, 472
 - postpartum, 474
 - in *Pneumocystis carinii* pneumonia, 468-470
 - in syphilis, 472
 - in toxoplasmosis, 470-471
 - in tuberculosis, 471-472
 - in military recruits, 435
 - opportunistic infections in, 468-472
 - in pregnancy
 - immune response in, 460-462
 - management of, 467-475
 - and outcome of pregnancy, 462-463
 - transmission to infants, 456-460, 481
 - prenatal counseling in, 445-451
 - checklist for, 453-455
 - prognosis of, 441-443
 - review questions, 517
 - risks for health care workers, 485-495
 - frequency of, 492
 - and management of exposures, 493-495
 - and modes of transmission, 485-488
 - and preventive measures, 488-491
 - tests for HIV antibody in, 425-428, 439-440, 446, 507-508
 - and controversies in screening, 498-501
 - in infants, 480
 - and posttest counseling, 448-451
 - prenatal, disadvantages of, 506-514
 - preoperative, 491
 - and pretest counseling, 447-448
 - transmission of
 - by blood exposure of nonintact skin, 486-487
 - by breast milk, 458-459, 474
 - to health care workers, 485-488
 - by needlestick injuries, 487-488
 - perinatal, 456-458, 481
 - by transfusions, 460
 - universal precautions in, 489
 - in labor and delivery, 489-490
 - in office settings, 489
 - in operating room, 490-491

- Alcohol abuse in pregnancy, and heart defects in infants, 42
- Amiloride in pregnancy, 17
- Amiodarone hydrochloride in pregnancy, 16
- Amniotic fluid index, 222, 239-240, 260
- Amniotic fluid volume in postdate pregnancy, 222-223
- assessment of, 238-239
- four-quadrant approach in, 239-240
- ultrasonography of, 260
- Amniotomy for labor induction, in postdate pregnancy, 270-271
- Ampicillin in endocarditis, in pregnancy, 51
- Anemia, iron deficiency, and oral contraceptive use, 350
- Anesthesia in labor
- cardiac output in, 71-72
- in patients with prosthetic heart valves, 86
- in rheumatic heart disease, 37
- Angina, and antianginal agents in pregnancy, 16-17
- Antiarrhythmic drugs in pregnancy, 15-16, 92-93
- Anticoagulants in pregnancy, 14, 97
- in atrial fibrillation, 35
- and fetal prognosis, 80
- in patients with prosthetic heart valves, 83, 85
- Aorta
- coarctation of, and pregnancy outcome, 44-45
- fetal blood flow in, assessment with ultrasound, 703-708
- absence of end-diastolic velocity in, 706-707
- in red cell isoimmunization, 721-724
- Aortic valve
- congenital stenosis of, and pregnancy outcome, 45-46
- insufficiency in rheumatic heart disease in pregnancy, 31-32
- Arrhythmias
- fetal, echocardiography in, 734
- in pregnancy, 89-101
- antiarrhythmic agents in, 15-16, 92-93
- atrial, 93-97
- fibrillation, 96-97
- flutter, 95-96
- paroxysmal supraventricular tachycardia, 94-95
- premature beats, 93-94
- in rheumatic heart disease, 27, 33-35
- and basic electrophysiology, 89-92
- conduction disorders, 99-100
- ventricular, 97-99
- fibrillation, 98-99
- premature beats, 97
- tachycardia, 97-98
- Arthritis, rheumatoid, and oral contraceptive use, 352
- Artificial insemination, 586-595
- controversies in, 587-589
- donor sperm in, 592-596
- and effects of cryopreservation of sperm, 594-595
- fresh vs frozen semen in, 592-593
- legal and ethical issues in, 615-616
- revised guidelines in, 593-594
- problems in, 591-592
- techniques in, 590-591
- theoretical goals in, 589-590
- Ashoff bodies in rheumatic fever, 23
- Asphyxia, perinatal, in postdate pregnancy, 232, 289
- Aspiration biopsy of breast, 786-798
- advantages of, 788-789
- in benign tumors, 795
- in cysts, 800-801
- disadvantages of, 789
- false-negative, 797
- false-positive, 797-798
- indications for, 786-788
- in inflammatory lesions, 794-795
- instrumentation in, 789-790
- interpretation of, 793-797
- in malignancies, 795-797
- in nonpalpable masses, 793
- in palpable masses, 791-793
- Atenolol in pregnancy, 16
- in atrial fibrillation, 35
- Atrial arrhythmias in pregnancy, 93-97
- in rheumatic heart disease, 27, 33-35
- Atrial septal defect, and pregnancy outcome, 43
- Autoimmune diseases, recurrent pregnancy loss in, 520-525
- Azidothymidine (AZT) in AIDS
- in pregnancy, 472
- as prophylaxis, 495
- Biopsy of breast, 783, 800-806
- cyst aspiration in, 800-801
- excisional, 805-806
- fine needle aspiration in, 786-798, 801-802. *See also* Aspiration biopsy of breast
- incisional, 802
- mammographic needle localization in, 802-805
- nipple, 806
- partial sampling of solid mass in, 801-802
- Tru-cut needle in, 802
- Birth control. *See* Contraception
- Birth trauma in postdate pregnancy, 290
- Birth weight in postdate infants, 231, 289
- legal considerations in, 299-300
- Bishop pelvic scoring system, 263, 270
- Bleomycin in papillomavirus infections, 216
- Blood flow analysis, fetal, Doppler ultrasonography in, 247-250, 627. *See also* Ultrasonography
- Blood transfusions
- fetal, hemodynamic changes from, 725-726
- and transmission of AIDS, 460
- Breast
- benign disease of, and oral contraceptive use, 348-349
- biopsy of, 783, 800-806. *See also* Biopsy of breast
- cancer of
- chemotherapy in
- endocrine therapy with, 844-847
- in node-negative carcinoma, 850-852
- in node-positive carcinoma, 837-842
- conservation surgery in, 807-817
- axillary operation in, 815-816
- in central "early" lesions, 812
- in ductal carcinoma in situ, 811, 826
- in elderly patients, 812
- in lobular carcinoma in situ, 811, 827
- in nonpalpable lesions, 811-812
- postoperative care in, 816-817
- in pregnancy, 812

- procedure in, 813-815
 and radiation oncology, 819-827
 rationale for, 808-809
 selection of patients for, 809-810
 special considerations in, 810-811
 specimen handling in, 816
 terminology in, 812-813
 endocrine therapy in
 chemotherapy with, 844-847
 in node-negative carcinoma, 852-853
 in node-positive carcinoma, 842-844
 epidemiology and risk factors in, 750-759
 familial, 750
 in males, 757
 gonadotropin releasing hormone agonists in, 560
 hereditary, 751, 752-759
 age at onset of, 752-753
 biomolecular studies in, 754-755
 extremely early onset of, 756-757
 management of, 758-759
 pedigree studies in, 753-754
 and prophylactic mastectomy, 758-759
 and SBLA syndrome, 755-756
 and injectable contraceptive use, 361-362
 modified radical mastectomy in, 830-834
 and oral contraceptive use, 343-345
 prophylactic mastectomy in, 758-759
 reconstruction after, 866-867
 review questions, 871-872
 examination of
 by physician, 761-764
 self-examination in, 765-767
 mammography of, 768-784. *See also* Mammography
 nipple discharge from, 764-765
 reconstruction after mastectomy, 858-869
 complications of, 867-868
 flaps in, 862-866
 nipple-areola in, 867
 in opposite breast, 866-867
 preoperative planning in, 858-859
 prosthetic implants in, 859-862
 refinement procedures in, 868-869
 tissue expansion in, 862
 stimulation for cervical priming in labor induction,
 264-265
 Breast-feeding, and transmission of AIDS, 458-459,
 474
 Breylium tosylate in pregnancy, 16
 in ventricular tachycardia, 98
 Buserelin, 551

 Calcium channel blockers in pregnancy, 16
 Cancer development
 and genital papillomavirus infection, 109-110, 114,
 123-124, 141-145
 and injectable contraceptive use, 361-362
 and oral contraceptive use, 342-345
 Candidiasis in AIDS during pregnancy, 471
 Cantharidine in papillomavirus infections, 216
 Captopril in pregnancy, 18
 Carcinoma
 of breast. *See* Breast, cancer of
 Cardiac output
 in anesthesia in labor, 71-72
 fetal, in red cell isoimmunization, 725
 heart rate affecting, 6-7
 Cardioplin, antibodies to, and recurrent pregnancy
 loss, 524-525
 Cardiomyopathy, peripartum, 54-66
 case history of, 59-60
 clinical features of, 56-59
 management of, 59-65
 antepartum, 61-63
 intrapartum, 63-65
 postpartum, 65
 pathophysiology of, 55-56
 Cardiovascular disease
 and injectable contraceptive use, 360
 and oral contraceptive use, 318-320, 341-342
 Cardiovascular physiology, 2-11
 afterload in, 5
 and contractility of heart, 5-6
 fetal, 728-730
 and heart rate affecting cardiac output, 6-7
 and hemodynamic monitoring, 8-9
 in pregnancy, 71, 679-680
 preload in, 4-5
 Cardioversion
 in atrial fibrillation, 96-97
 in pregnancy, 34
 in atrial flutter, 95-96
 in paroxysmal supraventricular tachycardia, 95
 in ventricular tachycardia, 98
 Carotid artery flow velocity, fetal, 710-717
 in red cell isoimmunization, 724-725
 Catheterization
 cardiac, in mitral stenosis, 30-31
 pulmonary artery, 8-9
 intrapartum, in rheumatic heart disease, 37-38
 in myocardial infarction, 73-74
 Cefazolin in endocarditis, in pregnancy, 51
 Cerebral blood flow, fetal, ultrasonography of, 710-
 717
 in red cell isoimmunization, 724-725
 Cervix uteri
 Bishop score for, 263, 270
 cancer of
 and genital papillomavirus infection, 109-110,
 114, 123-124, 141-145
 and oral contraceptive use, 342-343
 caps for contraception, 307, 382-383
 incompetence of, and recurrent pregnancy loss, 529
 mucus changes in menstrual cycle
 factors affecting, 397
 and family planning, 389-390, 391
 and ovulation prediction, 537
 priming for labor induction in postdate pregnancy,
 262-267
 Chemosurgery in papillomavirus infections, 219
 Chemotherapy in breast cancer
 in node-negative carcinoma, 850-852
 in node-positive carcinoma, 837-842
 endocrine therapy with, 844-847
 Chlorthalidone in pregnancy, 17
 Chlorothiazide in pregnancy, 17
 Chorionic gonadotropin, ovarian stimulation with,
 544-545

- Chromosome abnormalities, and absence of end-diastolic velocity in umbilical artery waveforms, 697-699
- Clomiphene citrate, ovarian stimulation with, 544
- Clonidine in pregnancy, 18
- Clotrimazole in candidiasis, in AIDS, 471
- Coagulation disorders, and anticoagulants in pregnancy, 14, 97
- Coarctation of aorta, and pregnancy outcome, 44-45
- Colchicine in papillomavirus infections, 207
- Computer use
- database management in, 607-608
 - desktop publishing and slides in, 606-607
 - expert system shells in, 608-610
 - in reproductive endocrinology, 610-612
 - telecommunications in, 610
 - word processing in, 605-606
- Condoms, 378-380
- efficacy of, 379
 - female, 380
 - instructions for use of, 378-380
- Conduction disorders in pregnancy, 99-100
- Condylomata acuminata. *See also* Papillomavirus infections, genital
- incidence of, 114
 - in males, 183-184
- Congenital anomalies
- and absence of end-diastolic velocity in umbilical artery waveforms, 697-699
 - and family planning issues, 397
 - in postdate pregnancy, 232, 260
- Contraception
- advisory panel to review vaginal products in, 384-385
 - barrier methods in, 377-385
 - and prevention of sexually transmitted diseases, 377-380
 - cervical cap in, 307, 382-383
 - and changes in public awareness, 314
 - condoms in, 378-380
 - current status in U.S., 305-306
 - diaphragms in, 307, 380-382
 - and toxic shock syndrome, 309, 381
 - douches in, 385
 - and family planning programs, 332
 - financial resources for, 332-336
 - and FDA decisions, 309-310, 311
 - proposals for changes in, 313
 - and global implications of controversy in, 312
 - gonadotropin-releasing hormone agonists in, 559-560
 - implants in, subdermal, 307, 365
 - injectable agents in, 306, 307, 356-366
 - and cancer development, 361-362
 - candidates for use of, 363
 - dose schedule for, 358
 - efficacy of, 358
 - and fertility return, 360-361
 - historical aspects of, 356-357
 - informed consent for, 362-363
 - in lactation, 361
 - menstrual changes from, 359
 - microspheres in, 365
 - mode of action, 358-359
 - monthly use of, 363-364
 - pharmacology of, 357-358
 - postpartum use of, 361
 - side effects of, 359-360
 - and teratogenicity concerns, 361
 - therapeutic uses of, 362
 - and insurance for product liability, 311
 - proposals for changes in, 312-313
- intrauterine devices in, 305, 307, 369-375
- benefits of, 371-372
 - compliance with, 372
 - cost of, 371-372
 - and ectopic pregnancy, 371
 - efficacy of, 371
 - infection from, 372-374
 - legal aspects of, 305, 307, 308
 - mechanical problems with, 374
 - mechanism of action, 370-371
 - pain and bleeding from, 374-375
 - Paragard, 314, 370
 - pregnancy with, 375
 - progesterone in, 369-370
 - risks with, 372-375
 - safety of, 372
 - timing for insertion of, 375
- legal aspects of, 307, 308-309
- proposals for changes in, 312-313
- medroxyprogesterone acetate in, 306, 356-366
- FDA decisions on, 309-310
- Norplant system in, 307, 314, 365
- oral agents in, 305, 316-326
- affecting lipid levels, 319-320, 321-322, 342
 - and benign breast disease, 348-349
 - breakthrough bleeding and spotting from, 322-324
 - and cancer development, 342-345
 - and cardiovascular disease, 318-320, 341-342
 - controversies in, 340-345
 - in dysfunctional uterine bleeding, 325
 - in dysmenorrhea, 325
 - and ectopic pregnancy, 346
 - efficacy of, 320-321
 - and endometrial cancer prevention, 347-348
 - in endometriosis, 325
 - formulations for, 316-317
 - guide for selection of, 324
 - and iron deficiency anemia, 350
 - and management of average patients, 325-326
 - metabolic effects of, 323-324
 - minipills in, 326
 - misperceptions of, 305, 309, 339-340
 - and osteoporosis, 351
 - and ovarian cancer prevention, 346-347
 - in ovarian cysts, 324-325, 350
 - and pelvic inflammatory disease, 349-350
 - and rheumatoid arthritis, 352
 - safety of, 317-318
 - side effects of, 322
 - therapeutic uses of, 324-325, 345-352
 - and toxic shock syndrome, 351
 - and uterine fibroids, 350-351
- and periodic abstinence methods, 387-399
- research funding in, 310, 314
- review questions, 414
- and RU 486 use, 308, 410-411
- spermicides in, 305, 307, 384

- with diaphragm use, 381
- legal considerations in, 308
- in vaginal sponges, 383
- vaginal sponges in, 383-384
- and world population problems, 329-337
- Contractility of heart, 5-6
- Contraction stress test in postdate pregnancy, 236-237
- Copper intrauterine contraceptive device, 370
- Corrigan's pulse in aortic insufficiency, 31
- Cortisol levels, RU 486 affecting, 405
- Coumarin derivatives in pregnancy, 14
- and fetal prognosis, 80
- Counseling
 - in congenital heart disease, 42
 - for prosthetic heart valve patients, 79-81
 - for women with HIV infection, 501-504
 - in prenatal testing for HIV antibodies, 445-451
 - checklist for, 453-455
- Cryopreservation
 - of embryos, 598-603
 - of semen for artificial insemination, 594-595
 - compared to fresh semen, 592-593
- Cryotherapy in papillomavirus infection, 208-209
- in males, 195
- Cyanosis in rheumatic heart disease, in pregnancy, 27
- Cysts
 - breast, needle aspiration of, 800-801
 - ovarian, oral contraceptives in, 324-325, 350
- Cytologic diagnosis
 - and aspiration biopsy of breast, 786-798
 - in papillomavirus infection, 148-156
 - in males, 181
- Dapsone in prophylaxis of *Pneumocystis carinii* pneumonia, 469
- Depo-Provera. *See* Medroxyprogesterone acetate as injectable contraceptive
- Diabetes, pregnancy in, and congenital heart defects in infants, 41
- Diaphragm, contraceptive, 308, 380-382
 - instructions for use of, 381-382
 - spermicides with, 381
 - and toxic shock syndrome, 309, 381
 - and urinary tract infections, 381
- Diazoxide in pregnancy, 18
- Digitalis preparations, electrophysiologic properties of, 92
- Digoxin
 - and contractility of heart, 6
 - electrophysiologic properties of, 92
 - in pregnancy, 15
 - in atrial fibrillation, 34-35
 - in paroxysmal supraventricular tachycardia, 94
- Diltiazem in pregnancy, 16
- Dinitrochlorobenzene (DNCB) in papillomavirus infections, 218
- Dipyridamole in pregnancy, 17
- Disopyramide phosphate in pregnancy, 16
- Diuretics in pregnancy, 17-18
- Diverticular disease of oviducts, 574
- DNA, recombinant, in papillomavirus studies, 127-139, 197-198
- Dobutamine, and contractility of heart, 6
- Doppler ultrasonography, 240, 245-253, *Al. See also* Ultrasonography
- Douches as ineffective contraceptives, 385
- Drug therapy in pregnancy, cardiovascular drugs in, 13-18, 92-93
- Ductus arteriosus patency, and pregnancy outcome, 43
- Duroziez sign in aortic insufficiency, 31
- Dysmenorrhea, oral contraceptives in, 325
- Dystocia, shoulder, in postdate pregnancy, 257-258, 281-283, 299-300
- Ebstein's anomaly, and pregnancy outcome, 44
- Echocardiography
 - in aortic insufficiency, 32
 - in endocarditis, 50
 - fetal, 728-735
 - in arrhythmias, 734
 - in cardiac anomalies, 733
 - in growth retardation, 735
 - in hydrops, 733-734
 - methods of examination in, 730-733
 - in normal pregnancy, 733
 - prostaglandin synthetase inhibition affecting, 735
 - in mitral stenosis, 28-30
- Ectopic pregnancy
 - and intrauterine contraceptive devices, 371
 - laser surgery in, 581-582
 - and oral contraceptive use, 346
- Edema, pulmonary, in rheumatic heart disease in pregnancy, 27, 35
- Eisenmenger syndrome, and pregnancy outcome, 44
- Electrical resistance, vaginal, and ovulation prediction, 537
- Electrocardiography
 - in aortic insufficiency, 32
 - in mitral stenosis, 28
- Electrocautery in papillomavirus infections, 208
- Embolism in rheumatic heart disease, in pregnancy, 27, 35
- Embryo
 - cryopreservation of, 598-603
 - cell damage and embryo survival in, 601-602
 - legal and ethical issues in, 620
 - nontechnical considerations in, 602-603
 - procedures in, 599-601
 - transfer from surrogate, 619-620
 - Encainide in pregnancy, 15
 - Endocarditis in pregnancy, 48-52
 - diagnosis of, 49-50
 - maternal and infant outcomes in, 50-51
 - pathogenesis of, 49
 - prophylaxis in, 52
 - in congenital heart disease, 46
 - with prosthetic heart valves, 85
 - in rheumatic heart disease, 37
 - treatment of, 51-52
 - Endocrinology, reproductive. *See* Infertility
 - Endometriosis
 - gonadotropin-releasing hormone agonists in, 552-554
 - laser surgery in, 579-580
 - oral contraceptives in, 325
 - Endometrium

- cancer of
 and injectable contraceptive use, 362
 and protective effects of oral contraceptives, 347-348
 laser photocoagulation of, 583-584
 RU 486 affecting, 403-404
 ultrasonography of, 547
- Endoscopic surgery in infertility, 564-575
 in fimbrial phimosis, 568-569
 proximal tube reconstruction in, 569-574
 salpingoovariolysis in, 567-568
 s^cpingostomy in, 569
- Estriol levels in postdate pregnancy, 224, 241
- Estrogen in oral contraceptives, 316-318
- Ethacrynic acid in pregnancy, 18
- Ethical issues
 in infertility treatment, 614-621
 in prevention of AIDS, 497-504
- Fallopian tubes
 diverticular disease of, 574
 endoscopic surgery in infertility, 564-575
 neosalpingostomy, 580-581
 polyps of, 574
 reanastomosis with laser welds, 582
 tubocornual anastomosis by microsurgery, 569-579
- Fallop tetralogy, and pregnancy outcome, 43-44
- Family planning
 contraception in. *See* Contraception
 periodic abstinence methods in, 387-399
- Fertility after injectable contraceptive use, 360-361
- Fertilization in vitro
 embryo cryopreservation in, 598-603
 gonadotropin-releasing hormone agonists in, 557-558
 legal and ethical issues in, 616-617
 ultrasonography in, 545-546
- Fetus
 blood flow studies with ultrasound, 247-250, 627
 echocardiography of, 728-735
 growth retardation in. *See* Growth retardation, intrauterine
 heart rate in
 amniotic fluid volume affecting, 222-223
 and cerebral blood flow, 714
 in postdate pregnancy, 225, 236-238, 279-280
 ultrasound affecting, 652-653
 ventricular function affected by amniotic fluid volume, 225
- Fibrillation
 atrial, in pregnancy, 96-97
 in rheumatic heart disease, 27, 33-35
 ventricular, in pregnancy, 98-99
- Fibroids, uterine
 gonadotropin-releasing hormone agonists in, 554-555
 laser surgery in, 583
 and oral contraceptive use, 350-351
- Fick equation, 7
- Flecainide in pregnancy, 15
- 5-Fluorouracil cream in papillomavirus infections, 206-207
 in males, 186-187
- Flutter, atrial, in pregnancy, 95-96
- Foley catheter in cervical priming for labor induction, 263-264
- Follicular growth and development, ovarian, 542-544
- Food and Drug Administration (FDA)
 decisions on contraceptives, 309-310, 311, 357
 proposals for changes in, 313
 panel to review vaginal contraceptives, 384-385
- Frank-Starling law of the heart, 4-5
- Furosemide in myocardial infarction, in pregnancy, 73
- Gamete intrafallopian transfer
 embryo cryopreservation in, 598-603
 ultrasonography in, 545-546
- Genetics
 and hereditary breast cancer, 751, 752-759
 and recurrent abortion, 529
- Genital papillomavirus infections. *See* Papillomavirus infections, genital
- Glucose tolerance
 injectable contraceptives affecting, 360
 oral contraceptives affecting, 323
- Glycosides, cardiac
 electrophysiologic properties of, 92
 in pregnancy, 15
- Gonadotropin, chorionic, ovarian stimulation with, 544-545
- Gonadotropin-releasing hormone agonists, 550-561
 in cancer, 560
 comparisons of, 551
 in contraception, 559-560
 diagnostic uses of, 560
 in endometriosis, 552-554
 in fibroids of uterus, 554-555
 indications for, 551
 in menstrual cycle-related illness, 559
 in ovulation induction, 556-558
 in polycystic ovarian disease, 556-557, 558
 in precocious puberty, 559
- Goserelin, 551
- Growth retardation, intrauterine
 cerebral blood flow in, 715-716
 echocardiography in, 735
 umbilical artery velocity waveforms in, 252, 660-667
- Health care workers
 risks for AIDS infection, 485-495
 risks for hepatitis B, 493
- Heart. *See also* Cardiac output
 fetal echocardiography, 728-735
- Heart block in pregnancy, 99-100
- Heart disease in pregnancy
 arrhythmias in, 89-101
 cardiomyopathy, 54-66
 and cardiovascular physiology, 2-11
 congenital disease, 41-52
 aortic stenosis, 45-46
 coarctation of aorta, 44-45
 counseling in, 42
 Ebstein's anomaly, 44
 Eisenmenger syndrome, 44
 endocarditis prophylaxis in, 46
 etiology of, 41-42
 idiopathic hypertrophic subaortic stenosis, 46
 Marfan syndrome, 45

- patent ductus arteriosus, 43
 septal defects, 43
 tetralogy of Fallot, 43-44
 drugs in, 13-18
 endocarditis in, 48-52
 myocardial infarction, 68-74
 prosthetic heart valves in, 76-87
 rheumatoid heart disease, 25-38
Heart failure in peripartum cardiomyopathy, 54-66
Heart rate
 affecting cardiac output, 6-7
 fetal
 amniotic fluid volume affecting, 222-223
 and cerebral blood flow, 714
 in postdate pregnancy, 225, 236-238, 279-280
Heart valve prostheses in pregnancy, 76-87
Hemodynamic monitoring in pregnancy, 8-9
 and fetal blood flow studies with ultrasound, 247-250, 627
Hemoglobin, oxygen dissociation from, 3
Hemoglobinopathy, injectable contraceptives in, 362
Hemorrhage, postpartum, in postdate pregnancy, 233
Heparin in pregnancy, 14, 97
 in patients with prosthetic heart valves, 83, 85
Hepatitis B, risks for health care workers, 493
Hereditary breast cancer, 751, 752-759
Herpes simplex virus infection in AIDS, during pregnancy, 470
Histerelin, 551
HLA antigens, and recurrent pregnancy loss, 525-526
Hydralazine in pregnancy, 5, 18
Hydrocephalus, and cerebral blood flow in fetus, 717
Hydrochlorothiazide in pregnancy, 17
Hydrops, fetal echocardiography in, 733-734
Hypertension in pregnancy
 and absence of end-diastolic velocity in umbilical artery waveforms, 696
 antihypertensive agents in, 18
 arterial velocity waveforms in, maternal and fetal, 679-685
 pulmonary, in rheumatic heart disease, 26
Hypnosis in papillomavirus infections, 210-211
Hypoglycemia in postdate infants, 290
Hypothermia in postdate infants, 290

Imidazole in candidiasis, in AIDS, 471
Immune response
 in AIDS
 in childhood, 479
 in pregnancy, 460-462
 in papillomavirus infection, 210
 in recurrent pregnancy loss, 525-526
Immunodeficiency disease, acquired. See AIDS
Immunology of HIV infections, 425-428
Immunotherapy in recurrent pregnancy loss, 527-529
Infarction, myocardial, in pregnancy, 68-74
Infection
 papillomavirus, genital, 105-221
 pelvic. *See* Pelvic inflammatory disease
 urinary tract, with diaphragm use, 381
Infertility
 artificial insemination in, 586-595
 donor sperm in, 592-595
 computer technology in, 610-612
 and embryo cryopreservation, 598-603
 gonadotropin-releasing hormone agonists in, 550-561
 legal and ethical issues in treatment programs, 614-621
 male factor, definition of, 587
 and ovulation prediction, 533-539
 and recurrent pregnancy loss, 520-530
 review questions, 623-624
 surgery in
 endoscopy in, 564-575
 lasers in, 564-566, 576-584
 and surrogate embryo transfer, 619-620
 and surrogate parenting, 617-619
 ultrasonography in, 541-547
Insemination, artificial, 586-595. See also Artificial insemination
Insurance costs for contraceptive product liability, 311
 proposals for changes in, 312-313
Interferon therapy in papillomavirus infections, 218-219
Intrauterine contraceptive devices, 369-375. See also Contraception, intrauterine devices in
Iron deficiency anemia, and oral contraceptive use, 350

Janeway spots in endocarditis, 49

Kaposi's sarcoma in AIDS, during pregnancy, 472
Kerley lines in mitral stenosis, 28
Ketoconazole in candidiasis, in AIDS, 471
Koilocytes in papillomavirus infection, 109, 148-149

Labetalol in pregnancy, 16
Labor
 anesthesia in
 affecting cardiac output, 71-72
 in patients with prosthetic heart valves, 86
 induction in postdate pregnancy, 235, 269-276
 cervical priming in, 262-267
 failure of, 279
 management of
 in AIDS, 472-474, 489-490
 in peripartum cardiomyopathy, 65
 in postdate pregnancy, 278-283
 in rheumatic heart disease, 37-38
Lactation
 and family planning, 396
 and injectable contraceptive use, 361
Lamical use in cervical priming for labor induction, 263
Laminaria tents, 263
Laparoscopic surgery in infertility, 564-575
Laplace law, 5
Laser use
 in adhesiolysis, 580
 in ectopic pregnancy, 581-582
 in endometrial ablation, 583-584
 in endometriosis, 579-580
 history of, 576
 in infertility surgery, 576-584
 in leiomyomata and uterine anomalies, 583
 in neosalpingostomy, 580-581
 in ovarian cysts, 582-583

- in papillomavirus infections, 209
 - in males, 186
- safety of, 578-579
- tissue reactions in, 564-566, 577-578
- in tubal reanastomosis, 582
- in uterosacral ligament ablation, 583
- Legal considerations
 - in contraception, 307, 308-309
 - proposals for changes in, 312-313
 - in infertility treatment, 614-621
 - and informed consent for injectable contraceptive use, 362-363
 - in postdate pregnancy, 294-301
 - and antenatal testing, 241
- Leiomyomata uteri
 - gonadotropin-releasing hormone agonists in, 554-555
 - laser surgery in, 583
 - and oral contraceptive use, 350-351
- Leukocytotoxic activity, antipaternal, and recurrent pregnancy loss, 526-527
- Leuprolide, 551
- Levamisole in papillomavirus infections, 209
- Lidocaine in pregnancy, 15
 - in myocardial infarction, 73
 - in ventricular tachycardia, 98
- Lipid levels
 - injectable contraceptives affecting, 360
 - oral contraceptives affecting, 319-320, 321-322, 342
- Lupus anticoagulant, and recurrent pregnancy loss, 521-524
- Lupus erythematosus in pregnancy, and heart defects in infants, 42
- Luteinizing hormone, urinary, in ovulation prediction, 537-538
- Luteinizing hormone-releasing hormone agonists, 550-561
- Macrosomia, fetal
 - diagnosis with ultrasound, 257-258
 - in postdate pregnancy, 231, 289
 - legal considerations in, 299-300
- Magnesium sulfate in pregnancy, interaction with cardiac medications, 100-101
- Males
 - condom use by, 378-380
 - familial breast cancer in, 757
 - genital papillomavirus infections in, 180-189
 - infertile, definition of, 587
- Mammography, 768-774
 - in altered breast, 783-784
 - benign masses in, 773
 - and biopsy decisions, 783
 - calcifications in
 - benign, 773
 - malignant, 777, 782
 - compliance with, 768-769
 - diagnostic uses of, 769-773
 - malignant masses in, 777-783
 - in needle localization in breast biopsy, 802-805
 - xeromammography compared to film screen in, 769
- Marfan syndrome, pregnancy outcome in, 45
- Mastectomy
 - breast reconstruction after, 858-869
 - modified radical, 830-834
 - prophylactic, 758-759
 - and reconstruction, 866-867
- Meconium
 - aspiration in postdate pregnancy, 289-290
 - passage in postdate pregnancy, 280-281
 - legal aspects of, 299-300
- Medroxyprogesterone acetate as injectable contraceptive, 306, 356-366
 - FDA decisions on, 309-310
- Membrane rupture, premature, in AIDS, 472
- Menstruation
 - changes from injectable contraception, 359
 - regulation with RU 486, 408-410
- Methyldopa in pregnancy, 18
- Methylene blue in papillomavirus infections, 207-208
- Metoprolol in pregnancy, 16
 - in atrial fibrillation, 35
- Mexiletine in pregnancy, 16
- Mitral stenosis in rheumatic heart disease, in pregnancy, 26-31
- Morphine in pregnancy
 - in myocardial infarction, 72-73
 - in pulmonary edema, 35
- Mucus, cervical, changes in menstrual cycle factors affecting, 397
 - and family planning, 389-390, 391
 - and ovulation prediction, 537
- Multiple pregnancy, umbilical artery velocimetry in, 687-690
- Myocardial infarction
 - and oral contraceptive use, 319, 341
 - in pregnancy, 68-74
 - acute management of, 72-73
 - causes of, 70-71
 - clinical features of, 68-70
 - poststabilization management in, 73-74
- Nadolol in pregnancy, 16
- Nicardipine in pregnancy, 16
- Nafarelin, 551
- Neosalpingostomy, 580-581
- Nifedipine in pregnancy, 16
- Nipple
 - biopsies of, 806
 - discharge from, 764-765
 - reconstruction with areola, 867
- Nitroglycerin in pregnancy, 16
- Nitroprusside sodium in pregnancy, 18
- Norethindrone enanthate as injectable contraceptive, 355
- Norplant as implantable contraceptive, 307, 308, 365
- Oligohydramnios
 - and cerebral blood flow in fetus, 716-717
 - in postdate pregnancy, 222-223
 - assessment of, 238-239
 - ultrasonography in, 260
- Oophorectomy in breast cancer, 842-843
- Osler's nodes in endocarditis, 49
- Osteoporosis, and oral contraceptive use, 351
- Ovaries
 - cancer of, and protective effects of oral contraceptive agents, 346-347

- cysts of, oral contraceptives in, 324-325, 350
 follicular growth and development in, 542-544
 in laparoscopic salpingoovariolysis, 567-568
 oophorectomy in breast cancer, 842-843
 polycystic disease of
 gonadotropin-releasing hormone agonist in, 558-559
 laser surgery in, 582-583
 ovulation induction in, 556-557
- Ovulation
 and basal body temperature, 391-392, 536-537
 induction of
 gonadotropin-releasing hormone agonists in, 556-558
 in polycystic ovarian disease, 556-557
 and ultrasonography in stimulated cycles, 544-545
 after injectable contraceptive use, 360-361
 prediction of, 533-539
 cervical mucus in, 537
 electrical resistance in, 537
 and family planning, 388
 need for, 533-536
 ultrasonography in, 538-539
 urinary LH kits in, 537-538
- Oxygen
 dissociation from hemoglobin, 3
 therapy in pulmonary edema, in pregnancy, 35
- Oxygenation of tissues, 2-4
- Oxytocin
 challenge test in postdate pregnancy, 236
 in labor induction, 272-273, 279
- Papillomavirus infections, genital, 105-212
 abortive cell/virus interaction in, 164-165
 acetowhite epithelium in males, 183
 active expression phase in, 158-159
 asperities in
 in males, 183
 and benign tumors, 141-142
 biology of, 158-161
 bleomycin in, 216
 and cancer, 109-110, 114, 123-124, 141-145
 cofactors in, 143-144
 cantharidine in, 207
 cervical transformation zone in, 165-167
 chemosurgery in, 210
 clinical features of preinvasive disease, 169-173
 cofactors in, 143-144, 201-202
 colchicine in, 216
 colposcopic grading of, 173-178
 containment phase in, 159
 cryotherapy in, 208-209
 cytologic diagnosis of, 149-151
 in males, 181
 dinitrochlorobenzene in, 209
 electrocautery in, 208
 epidemiology of, 112-115
 5-fluorouracil cream in, 206-207
 in males, 186-187
 high-grade lesions in, 167
 immune system in, 201
 incidence of, 114-115
 individual differences in disease expression in, 161-165
 inoculation and incubation in, 158, 200-201
 interferon therapy in, 209-210
 iodine staining reactions in, 171-172
 laser therapy in, 209
 in males, 186
 late phase in, 161
 latent infections in, 162-163, 202
 levamisole in, 209
 local excision in, 209
 low-grade lesions in, 167-169
 in males, 180-189
 biopsy in, 182
 cytologic examination in, 181
 differential diagnosis of, 184-185
 relation to lesions in females, 188-189
 symptoms of, 180-181
 treatment of, 185-188
 methylene blue dye in, 207-208
 microscopic diagnosis of, 148-156
 cytologic smears in, 149-151, 181
 histologic sections in, 151-154
 sensitivity of, 154-156
 minimally expressed infections in, 163
 natural history of, 113-114, 200-203
 podophyllin in, 205-206
 in males, 186
 in pregnancy, 191-198
 and anogenital warts in offspring, 193-194
 clinical features of, 191-192
 and juvenile laryngeal papilloma in offspring, 192-193
 management of, 195-197
 risk of transmission to fetus, 194-195
 prevention of, 203
 radiation therapy in, 211
 research milestones in, 107-110
 relationship between lesions in men and women, 188-189
 risk factors in, 112
 spontaneous regression of, 202-203
 studies with recombinant DNA technology, 127-139, 197-198
 dot blot hybridization in, 131, 197
 filter in situ hybridization in, 131-133
 gene amplification in, 131
 in situ hybridization in, 133-137
 Northern blot hybridization in, 131
 practicability of methods in, 138-139
 selection of hybridization method in, 137-138
 Southern blot hybridization in, 129-131
 type-specific antigens in, 139
 subclinical infection in, 114-115, 202
 subtypes of virus in, 108-109, 120, 201
 suggestion and hypnosis in, 210-211
 transmission of, 107, 112-113, 200
 treatment of, 203-212
 in males, 185-188
 in pregnancy, 195-197
 trichloroacetic acid in, 206
 in males, 186
 vaccine in, 200
 vascular patterns in, 171
 vegetative infections in, 164
 virology of, 117-125
 basic properties, 117-118

- classification, 118-120
- genetic organization, 121-123
- life cycle, 120-121
- vulvectomy in, 209
- well-developed infections in, 163-164
- Paragard intrauterine contraceptive device, 314, 370
- Parity, and postdate pregnancy incidence, 230
- Pelvic inflammatory disease
 - and injectable contraceptive use, 361
 - from intrauterine contraceptive devices, 372-374
 - and oral contraceptive use, 349-350
- Penicillin
 - in endocarditis in pregnancy, 51
 - in rheumatic fever prophylaxis, 25
- Pentaerythritol in pregnancy, 16
- Pentamidine isethionate in *Pneumocystis carinii* pneumonia in AIDS, 469
- Pericarditis, rheumatic, 23
- Phenylketonuria in pregnancy, and heart defects in infants, 42
- Phimosi, fimbrial, laparoscopic surgery in, 568-569
- Placenta in postdate pregnancy, 223-224, 233, 259
- Pneumocystis carinii* pneumonia in AIDS, in pregnancy, 468-470
- Podophyllin in papillomavirus infections, 205-206
 - in males, 186
- Polycystic ovarian disease
 - gonadotropin-releasing hormone agonist in, 558-559
 - laser surgery in, 582-583
 - ovulation induction in, 556-557
- Polycythemia in postdate infants, 290
- Polyps, tubal, 574
- Population problems, global, 329-337
- Postdate pregnancy
 - age in, maternal, 230
 - amniotic fluid index in, 222, 239-240, 260
 - amniotic fluid volume in, 222-223
 - assessment of, 238-239
 - ultrasonography of, 260
 - antenatal assessment in, 235-241
 - legal aspects of, 241, 297-299
 - asphyxia in, perinatal, 232, 289
 - biophysical profile test in, 239
 - birth injuries in, 290
 - and birth weight of infants, 231, 289
 - congenital anomalies in, 232, 260
 - contraction stress test in, 236-237
 - definition of, 228, 285
 - epidemiology of, 228-233
 - estriol levels in, 224, 241
 - etiology of, 229-230
 - fetal factors in, 231-233
 - heart rate in, fetal, 225, 279-280
 - and hypoglycemia in infants, 290
 - and hypothermia in infants, 290
 - incidence of, 221, 228, 285-286
 - intrapartum management of, 278-283
 - labor induction in, 235, 269-276
 - acupuncture in, 271
 - amniotomy in, 270-271
 - breast stimulation in, 264-265
 - cervical priming in, 262-267
 - decadron in, 272
 - failure of, 279
 - Foley catheter in, 263-264
 - laminaria tents in, 263
 - oxytocin in, 272-276, 279
 - and preinduction evaluation, 269-270
 - prostaglandin E₂ in, 265-266, 272
 - relaxin in, 264, 272
 - stripping of membranes in, 262-263, 270
 - legal considerations in, 294-298
 - long-term outcome of, 290-292
 - macrosomia in, fetal, 231, 257-258, 289
 - legal aspects of, 299-300
 - management of, 225-226
 - maternal factors in, 230-231
 - meconium aspiration in, 289-290
 - meconium passage in, 280-281
 - legal aspects of, 300-301
 - morbidity and mortality in, perinatal, 232-233, 287-290
 - nonstress test in, 237-238
 - oxytocin challenge test in, 236
 - physiologic changes in, 222
 - placenta in, 223-224, 233, 259
 - and polycythemia in infants, 290
 - and postmaturity syndrome in infants, 228, 231-232, 258-260, 286-287
 - postpartum hemorrhage in, 233
 - review questions, 303-304
 - shoulder dystocia in, 257-258, 281-283, 299-300
 - ultrasonography in, 257-261
 - umbilical cord dimensions in, 224-225
 - weight gain in, 231
- Postmaturity syndrome in infants, 228, 231-232, 258-260, 286-287
- Postpartum period
 - AIDS management in, 474
 - hemorrhage in postdate pregnancy, 233
 - injectable contraceptives in, 361
 - sterilization in
 - in patients with prosthetic heart valves, 87
 - in peripartum cardiomyopathy, 65
- Pregnancy
 - AIDS in. *See* AIDS
 - breast cancer in, 812
 - cardiovascular drugs in, 13-18, 92-93
 - cardiovascular system in, 71, 679-680
 - ectopic. *See* Ectopic pregnancy
 - heart disease in. *See* Heart disease in pregnancy
 - hemodynamic monitoring in, 8-9
 - and fetal blood flow studies with ultrasound, 247-250, 627
 - hypertension in. *See* Hypertension in pregnancy
 - papillomavirus lesions in, 200-207
 - postdate. *See* Postdate pregnancy
 - ultrasonography in. *See* Ultrasonography
- Preload, cardiac, 4-5
- Premature beats in pregnancy
 - atrial, 93-94
 - ventricular, 97
- Premature rupture of membranes in AIDS, 472
- Premenstrual syndrome, gonadotropin-releasing hormone agonists in, 559
- Procainamide in pregnancy, 15
 - in atrial flutter, 96
 - in ventricular tachycardia, 98

- Progesterone
 antagonists as abortifacients, 403-412
 in intrauterine contraceptive device, 369-370
 Progestins in oral contraceptives, 316-318
 Propranolol in pregnancy, 15-16
 in paroxysmal supraventricular tachycardia, 94-95
 Prostaglandin(s)
 in labor induction, 265-266, 272
 RU 486 with, for abortion induction, 408
 Prostaglandin synthetase inhibition affecting fetal echocardiography, 735
 Prostatic carcinoma, gonadotropin-releasing hormone agonists in, 560
 Prosthetic heart valves, 76-87
 counseling in, 79-81
 endocarditis prophylaxis in, 85
 in pregnancy
 anteartum management in, 81-83
 and anticoagulation, 83, 85
 fetal surveillance in, 83-84
 intrapartum management in, 84-87
 postpartum management in, 87
 replacement surgery in, 84
 pregnancy affecting, 76-77
 prepregnancy evaluation of, 78-79
 types of, 77-78
 Prosthetic implants in breast reconstruction, 859-862
 Puberty, precocious, gonadotropin-releasing hormone agonists in, 559
 Pulmonary artery catheterization, 8-9
 Pyrimethamine-sulfadiazine
 in prophylaxis of *Pneumocystis carinii* pneumonia, 469
 in toxoplasmosis in pregnancy, 471

 Quincke's pulse in aortic insufficiency, 31
 Quinidine in pregnancy, 15
 in atrial fibrillation, 34-35
 in atrial flutter, 96

 Radiation therapy
 and breast conservation therapy, 819-827
 in papillomavirus infections, 211
 Radiography
 in aortic insufficiency, 32
 in mitral stenosis, 28
 Relaxin for labor induction, 264, 272
 Reproductive endocrinology. *See* Infertility
 Research, computer use in, 611-612
 Rh isoimmunization, fetal blood flow studies in, 719-727
 after blood transfusion, 725-726
 Rheumatic fever, 21-25
 antibiotic prophylaxis in, 25
 Aschoff bodies in, 23
 clinical features and diagnosis of, 23-25
 coronary arteritis in, 23
 course and prognosis of, 25
 etiology of, 21-22
 myocardial lesions in, 23
 pathophysiology of, 22
 pericarditis in, 23
 verrucous endocardial lesions in, 23

 Rheumatic heart disease in pregnancy, 25-38
 aortic insufficiency in, 31-32
 diagnosis of, 32
 valve replacement in, 36
 endocarditis prophylaxis in, 37
 fetal complications from, 36
 incidence of, 25-26
 management of, 32-38
 anteartum, 32-37
 intrapartum, 37-38
 mitral stenosis in, 26-31
 atrial fibrillation in, 27, 33-35
 clinical features of, 27
 diagnosis of, 28-31
 pathophysiology of, 26-27
 physical findings in, 27
 valve replacement in, 36
 Rheumatoid arthritis, and oral contraceptive use, 352
 Rhythm method, calendar-based, for family planning, 388-389
 Roth spots in endocarditis, 49
 RU 486, 403-412
 abortion induction with, 308, 405-406
 mechanisms in, 406-407
 prediction of success in, 407-408
 prostaglandins with, 408
 antiglucocorticoid activity of, 405
 contraception with, 410-411
 effects on endometrium, 403-404
 as menses regulator, 409-410
 noncontraceptive uses of, 411
 pharmacokinetics of, 404-405
 Rubella in pregnancy, and heart defects in infants, 42

 Salpingoovariolysis, laparoscopic, 567-568
 Salpingostomy, laparoscopic, 569
 Semen
 computerized analysis of, 611
 donor, for artificial insemination, 592-595
 fresh or frozen, for artificial insemination, 592-593
 Sexual activity
 contraception in. *See* Contraception
 and periodic abstinence for family planning, 387-399
 and "safer sex" practices, 447-448, 450
 Sexually transmitted diseases
 genital papillomavirus infection, 107, 112-113, 200
 immunodeficiency disease. *See* AIDS
 and use of barrier contraceptives, 377-378
 Shoulder dystocia in postdate pregnancy, 257-258, 281-283, 299-300
 Sickle cell disease, injectable contraceptives in, 362
 Smoking, and oral contraceptive use, 319, 343
 Socioeconomic status, and postdate pregnancy incidence, 230
 Spermicides, 305, 307, 384
 with diaphragm use, 381
 legal considerations with, 308
 in vaginal sponges, 383
 Spiramycin in toxoplasmosis, in pregnancy, 471
 Spironolactone in pregnancy, 17
 Sponges, vaginal, 383-384
 Sterilization, postpartum
 in patients with prosthetic heart valves, 87
 in peripartum cardiomyopathy, 65

- Streptococcal infection, and rheumatic fever, 21-22
- Streptokinase in pregnancy, 14
- Strokes, and oral contraceptive use, 341
- Sulfadiazine-pyrimethamine
in prophylaxis of *Pneumocystis carinii* pneumonia, 469
in toxoplasmosis in pregnancy, 471
- Sulfamethoxazole-trimethoprim in *Pneumocystis carinii* pneumonia, 469
- Surgery
for AIDS patients, protective measures in, 490-491
in breast cancer
conservation of tissue in, 807-817
modified radical mastectomy in, 830-834
in infertility
endoscopy in, 564-575
lasers in, 564-566, 576-584
- Surrogate embryo transfer, legal and ethical issues in, 619-620
- Surrogate parenting, legal and ethical issues in, 617-619
- Syphilis in AIDS, during pregnancy, 472
- Tachycardia in pregnancy
paroxysmal supraventricular, 94-95
ventricular, 97-98
- Tamoxifen in breast cancer
in node-negative carcinoma, 852-853
in node-positive carcinoma, 843-844
- Temperature
basal body, and ovulation, 391-392, 536-537
and hypothermia in postdate infants, 290
- Tetralogy of Fallot, and pregnancy outcome, 43-44
- Thiazide diuretics in pregnancy, 17
- Thrombocytopenia in AIDS, 472
- Thromboembolism
and injectable contraceptive use, 360
and oral contraceptive use, 318-319, 341
- Thrombolytic agents in pregnancy, 14
- Timolol in pregnancy, 16
- Toxic shock syndrome
from diaphragm use, 309, 381
and oral contraceptive use, 351
- Toxoplasmosis in AIDS, during pregnancy, 470-471
- Transfusions
fetal, hemodynamic changes from, 725-726
and transmission of AIDS, 460
- Triamterene in pregnancy, 17
- Trichloroacetic acid in papillomavirus infections, 206
in males, 186
in pregnancy, 196
- Trimethoprim-sulfamethoxazole in *Pneumocystis carinii* pneumonia, 469
- Tryptorelin, 551
- Tuberculosis in AIDS, during pregnancy, 471-472
- Twin pregnancy, umbilical artery velocimetry in, 687-690
- Ultrasonography, 240, 245-253
absence of end-diastolic velocity in
in fetal descending aorta, 706-707
in umbilical artery, 692-700
amniotic fluid index in, 222, 239-240, 260
aortic blood flow in, fetal, 703-708
in red cell isoimmunization, 721-724
arterial velocity waveforms in hypertensive pregnancy, 679-685
backscattering in, 630
biologic effects of, 645-656
in experimental insonation, 649-652
in humans, 652-653
cavitation from, 647-649
cerebral blood flow studies in fetus, 710-717
breathing movements affecting, 711
in growth retardation, 715-716
heart rate affecting, 714
in hydrocephalus, 717
in normal pregnancy, 715
in oligohydramnios, 716-717
in sleep, 711-714
vibratory acoustic stimulation affecting, 714-715
color flow mapping in, 635
continuous wave, 632-633
Doppler effect in, 630
echocardiography, fetal, 728-735
endometrial scanning in, 547
equipment for, 245-246
factors affecting indices in, 640-642
in fetal blood flow analysis, 247-250, 627
of follicular growth and development, 542-544
in stimulated cycles, 544-545
technique in, 541-542
in gamete intrafallopian transfer, 546-547
in hemodynamic assessment, 636-638
in invitro fertilization program, 545-546
in macrosomia diagnosis in fetus, 257-258
in oligohydramnios, 260
in ovulation abnormalities, 547
in ovulation prediction, 538-539
peripheral resistance evaluation in, 250-251
in postdate pregnancy, 257-261
in postmaturity syndrome, 258-260
in prenatal diagnosis of congenital anomalies, 260
principles of, 246-247, 628-642
pulsed wave, 633-635
recommendations of American Institute of Ultrasound in Medicine, 654-656
in red cell isoimmunization, 719-727
after fetal blood transfusions, 725-726
review questions, 747
side effects of, 547
thermal effects of, 646-647
umbilical artery flow velocity in, 251-253, 738-744. *See also* Umbilical artery flow velocity waveforms
uterine artery flow velocity in, 738-744. *See also* Uterine artery flow velocity waveforms
waveform analysis in, 638-640
Umbilical artery flow velocity waveforms, 251-253, 738-744
absence of end-diastolic velocity in, 692-700
in chromosomal and congenital anomalies, 697-699
in hypertension, 696
and perinatal outcome, 694-696
compared to nonstress test, 743-744
correlation with uterine artery waveform, 669-676
effects of abnormalities in, 739
in growth retarded fetus, 660-667
in hypertensive pregnancy, 679-685

CUMULATIVE INDEX

- incidence of abnormalities in, 742-743
- in multiple pregnancy, 687-690
- in red cell isoimmunization, 720
- Umbilical cord dimensions in postdate pregnancy, 224-225
- Umbilical venous velocity in red cell isoimmunization, 720-721
- Urinary tract infection with diaphragm use, 381
- Urokinase in pregnancy, 14
- Uterosacral ligament ablation with lasers, 583
- Uterine artery flow velocity waveforms, 738-744
 - correlation with umbilical artery waveform, 669-676
 - effects of abnormalities in, 739
 - in hypertensive pregnancy, 679-685
 - incidence of abnormalities in, 742-743
 - in red cell isoimmunization, 720
- Uterus. *See also* Cervix uteri; Endometrium
 - contraceptive devices in. *See* Contraception, intra-uterine devices in
 - fibroids of. *See* Fibroids, uterine
 - septate
 - laser surgery in, 583
 - and recurrent pregnancy loss, 529
- Vaccine in papillomavirus infections, 219
- Vagina
 - electrical resistance in, and ovulation prediction, 537
- Valvular prostheses, cardiac, in pregnancy, 76-87
- Vancomycin in endocarditis, in pregnancy, 51
- Vena cava, inferior, fetal flow velocity waveforms in red cell isoimmunization, 721
- Ventricular arrhythmias in pregnancy, 97-99
- Ventricular function, 5
 - fetal, amniotic fluid volume affecting, 225
- Ventricular septal defect, and pregnancy outcome, 43
- Verapamil in pregnancy, 16
 - in atrial fibrillation, 34
 - in paroxysmal supraventricular tachycardia, 94
- Verrucous carcinoma of vulva, 186
- Verrucous endocardial lesions in rheumatic fever, 23
- Vulvectomy in papillomavirus infections, 218
- Warts, viral etiology of, 107-108. *See also* Papillomavirus infections, genital
- Weight
 - at birth, in postdate infants, 231, 289
 - legal considerations in, 299-300
 - maternal, at delivery of postdate infant, 231
- Wolff-Parkinson-White syndrome in pregnancy, 99

AUTHOR INDEX

- Ahn, Myoung Ock, 228
 Albain, Kathy S., 835
 Annas, George J., 614
 Ball, G. David, 598
 Bardin, C. W., 403
 Bayer, Ronald, 497
 Beahrs, Oliver H., 830
 Berthaud, Marise, 445
 Bilardo, Caterina M., 719
 Brady, Kim, 21
 Branch, D. Ware, 520
 Brar, Harbinder S., 245
 Briggs, Robert M., 858
 Brown, Charles E. L., 89
 Campbell, Stuart, 719
 Champion, Michael J., 157
 Cancellieri, Frank, 445
 Clark, Steven L., 278
 Connell, Elizabeth B., 377
 Cooper, Richard A., 768
 Cotton, David B., 54
 Coury, Anne, 687, 738
 Cox, Susan M., 48
 Ducey, James, 679
 Dudley, Donald J., 520
 Duff, Patrick, 21
 Eden, Robert D., 235
 Elias, Sherman., 614
 Farmakides, George, 687, 738
 Feinkind, Leonard, 467
 Ferenczy, Alex, 191
 Fleischer, Adiel, 627, 660
 Folk, Frank A., 807
 Giles, Warwick B., 669
 Gilstrap, Larry C., III, 1, 13, 41
 Gissmann, Lutz, 141
 Grimes, David A., 305, 369
 Grubert, Thomas, 127
 Grunert, George M., 576
 Guidetti, Denise, 660
 Hankins, Gary D. V., 2, 68, 269
 Hecht, Bryan R., 541
 Herbst, Arthur L., 800
 Hoffman, David I., 541
 Holman, Susan, 445
 Isaacs, John H., 749, 761
 Jacobs, Laurence A., 586
 Jelovsek, Frederick R., 605
 Jouppila, Pentti, 703
 Faunitz, Andrew M., 356
 Kenigsberg, Daniel, 533
 Kirkinen, Pertti, 703
 Krebs, Hans-B., 105, 107, 180, 200
 Kuske, Robert R., 819
 Labbok, Miriam H., 387
 Lee, Nancy C., 339
 Lee, Raymond A., 830
 Lee, Wesley, 54
 Leveno, Kenneth J., 48
 Listernick, Joan I., 506
 Little, Bertis B., 13
 Lotze, Eberhard C., 576
 Lynch, Henry T., 750
 Lynch, Jane F., 750
 Maberry, Mark C., 41
 Martin, James N., Jr., 76
 Maulik, Dev, 628, 645
 McColgin, Sterling W., 76
 McComb, Peter F., 564
 Mead, Philip B., 485
 Mesogitis, Spyros, 687
 Minkoff, Howard L., 421, 456, 467
 Moroso, Gail, 445
 Morrison, John C., 76
 Nanda, Deepak, 456
 Nicolaides, Kypros H., 719
 Nolan, Thomas E., 68
 Ory, Steven J., 519, 586
 Penny, Barbara, 738
 Peterson, Herbert B., 339
 Phelan, Jeffrey P., 219, 221, 228, 294
 Porto, Manuel, 262
 Potts, Malcolm, 329
 Queenan, John T., 387
 Ramin, Susan M., 41
 Reed, Kathryn L., 728
 Reid, Richard, 157
 Rochelson, Burton, 692
 Rodriguez, M. Hellen, 257
 Salas, Julie E., 307
 Satin, Andrew J., 269
 Schneider, Achim, 127
 Schneider, Elizabeth, 687, 738
 Schneider, Volker, 148
 Schriock, Eldon D., 550
 Schulman, Harold, 687, 738
 Scott, Gwendolyn B., 477
 Settlage, Robert Hurd, 437
 Sever, John L., 423
 Sims, Maureen E., 285
 Smotkin, David, 117
 Spitz, Irving M., 403

AUTHOR INDEX

Stone, Katherine M., 112
Stubblefield, Phillip G., 316
Stuhlmuller, Patricia, 660
Sunderland, Ann, 445
Trudinger, Brian J., 669
Tyrer, Louise B., 307
Walloch, Jami, 786

Walther, Frans J., 285
Watson, Patrice, 750
Wendel, George D., 89
Willoughby, Anne, 429
Winter, Denise, 738
Wladimiroff, J. W., 710
Yeomans, Edward R., 2

